Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET. The event will be webcasted live and accessible through the investor and media section of Esperion's website. A replay will be available approximately two hours after the call and archived for about 90 days.
Esperion is a pharmaceutical company focused on developing innovative medicines for cardiovascular and cardiometabolic diseases. Their mission is to help patients with high cholesterol reach their health goals by providing next-step solutions in reducing LDL-cholesterol levels. The company emphasizes the importance of lowering cholesterol levels as much as possible, as quickly as possible.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ESPR declined 0.56%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 8:30 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) participating in the H.C. Wainwright Global Investment Conference?
How can investors access Esperion's (ESPR) presentation at the H.C. Wainwright conference?
How long will the replay of Esperion's (ESPR) conference presentation be available?
What is the main focus of Esperion's (ESPR) pharmaceutical research?
